目的:本研究的目的是调查视网膜静脉阻塞(RVO)患者玻璃体视网膜界面(VRI)疾病的患病率,并评估VRI异常对治疗结果的影响。
方法:这项前瞻性研究的参与者是连续的RVO继发黄斑水肿患者,他接受了玻璃体内注射阿柏西普。在基线,评估最佳矫正视力(BCVA),和谱域光学相干断层扫描(SD-OCT)进行测量中心子场厚度(CST)和评估是否存在VRI疾病,即,玻璃体视网膜粘连(VMA),玻璃体视网膜牵引(VMT),视网膜前膜(ERM),层状黄斑裂孔(LMH),和全厚度黄斑裂孔(FTMH)。主要结果是RVO患者中各种VRI疾病的患病率以及此类患者在接受阿柏西普治疗后VRI疾病对BCVA和CST的影响。
结果:在基线时,16.1%的患者有VMA,3.2%VMT,18.3%ERM,和1.1%LMH。随着时间的推移,RVO患者的BCVA有统计学上的显着改善,CST下降。在基线时和直到治疗后24个月时,在有VRI障碍的患者和没有VRI障碍的患者之间,关于BCVA和CST没有统计学上的显著差异。然而,在随访期间,VRI障碍组的平均注射次数(9.4±2.1)高于无VRI障碍组(8.1±0.7,p=0.0002).
结论:RVO患者的VRI疾病患病率为16.1%,VMT为3.2%,ERM的18.3%,LMH为1.1%。在患有RVO的患者中,玻璃体内阿柏西普治疗后,未发现VRI疾病会影响解剖和视觉结果。尽管VRI疾病患者需要更多的玻璃体内注射.
OBJECTIVE: The purpose of this study is to investigate the prevalence of vitreoretinal interface (VRI) disorders in patients with retinal vein occlusion (RVO) and to evaluate the impact of VRI abnormalities on the treatment outcomes of macular edema secondary to RVO using intravitreal aflibercept.
METHODS: Participants in this prospective study were consecutive patients with macular edema secondary to RVO, who received intravitreal aflibercept injections. At baseline, best-corrected visual acuity (BCVA) was assessed, and spectral domain-optical coherence tomography (SD-OCT) was performed to measure central subfield thickness (CST) and to evaluate the presence of VRI disorders, namely, vitreoretinal adhesion (VMA), vitreoretinal traction (VMT), epiretinal membrane (ERM), lamellar macular hole (LMH), and full-thickness macular hole (FTMH). The primary outcomes were the prevalence of various VRI disorders in patients with RVO and the impact of VRI disorders on BCVA and CST after aflibercept treatment in such patients.
RESULTS: At baseline, 16.1% of patients had VMA, 3.2% VMT, 18.3% ERM, and 1.1% LMH. There were a statistically significant improvement in BCVA and a decrease in CST in RVO patients over time. There was no statistically significant difference regarding BCVA and CST at baseline and until month 24 after treatment between patients with VRI disorders and those without VRI disorders. However, the mean number of injections during the follow-up period was higher in the group with VRI disorders (9.4±2.1) compared to those without VRI disorders (8.1±0.7, p=0.0002).
CONCLUSIONS: The prevalence of VRI disorders in patients with RVO was 16.1% for VMA, 3.2% for VMT, 18.3% for ERM, and 1.1% for LMH. VRI disorders were not found to affect the anatomical and visual outcomes after intravitreal aflibercept treatment in patients with RVO, although more intravitreal injections were needed in patients with VRI disorders.